Zucara Therapeutics Successfully Completes Single and Multiple Ascending Dose Phase 1 Trial of ZT-01 Toronto, Canada, May 26, 2021 – Zucara Therapeutics Inc. (“Zucara” or the “Company”), a diabetes life […]
Zucara Therapeutics Successfully Completes Single and Multiple Ascending Dose Phase 1 Trial of ZT-01 Toronto, Canada, May 26, 2021 – Zucara Therapeutics Inc. (“Zucara” or the “Company”), a diabetes life […]
Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes – ZT-01 Development for T2D to be Supported by Nearly $450K in Non-Dilutive Funding – Toronto, Canada, November 2, 2020 […]
Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01 – Phase 1 Trial to Evaluate ZT-01 for the Prevention of Insulin-Induced Hypoglycemia in Patients with Type 1 Diabetes […]
Zucara Therapeutics Announces US$21 Million Series A Financing – Proceeds to Fund Development of ZT-01 Through Phase 2 Clinical Trials – – Series A Financing led by the Perceptive Xontogeny […]
Dr. Richard Liggins, Chief Scientific Officer, presenting at EASD in Barcelona. TORONTO, Canada and BARCELONA, Spain: Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent […]
Toronto & Vancouver, Canada: Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with type 1 diabetes and other types of insulin-dependent […]
(Michael Midmer & Dr. Mladen Vranic) Dr. Mladen Vranic, a leading scientist and advocate for the advancement of diabetes research, and teacher of innumerable renowned scientists and academic leaders, helped […]
TORONTO, Canada: Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with Type 1 diabetes and other types of insulin-dependent diabetes, is […]
Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with Type 1 diabetes and other types of insulin-dependent diabetes, is pleased to […]
Typically occurring overnight, hypoglycemia puts over 8 million people with diabetes at fatal risk during their sleep. Current therapies offer hypoglycemic treatment only once an episode occurs. Zucara is working […]
